Clinical analysis of Shuganjieyu Decoction combined with entecavir in the treatment of chronic hepatitis B
Objective:To explore the clinical effect of Shuganjieyu Decoction and entecavir combination therapy on chronic hepatitis B.Methods:168 patients with chronic hepatitis B admitted to Department of Hepatology of Dengzhou Hospital of Traditional Chinese Medicine from January 2021 to May 2023 were selected and divided into the control group and the test group according to the random number table,84 patients in each group.The control group was treated with Entecavir,while the experimental group was treated with Shuganjieyu Decoction on this basis.The treatment effects,traditional Chinese medicine syndrome scores,liver function indicators,virological indicators,and incidence of adverse reactions were compared in both groups.Result:Compared with control group,the total effective rate of the experimental group(97.62%)was higher(86.90%)(P<0.05).The TCM syndrome scores,serum alanine aminotransferase(ALT),aspartate aminotransferase(AST),and total bilirubin(TBil)of experimental group was lower than the control group after treatment(P<0.05).After treatment,compared with control group,the levels of hepatitis B virus surface antigen(HBsAg)and hepatitis B virus deoxyribonucleic acid(HBV-DNA)in the experimental group were lower,and compared with control group(89.29%),the HBV-DNA conversion rate was higher(P<0.05).The incidence of adverse reactions between the two groups was not significantly different(P>0.05).Conclusion:The combination treatment of Shuganjieyu Decoction and entecavir for chronic hepatitis B patients can effectively reduce the TCM syndrome score of patients,optimize liver function indicators,effectively inhibit the replication of hepatitis B virus,promote the negative transformation of HBV DNA,and improve the overall efficacy.
Shuganjieyu DecoctionEntecavirChronic hepatitis BTherapeutic effectLiver function
NETL
NSTL
万方数据
